and exacerbates portal hypertension. Gastro esophageal varices are the most important col laterals, because as pressure and flow increase through them, they grow and eventually rupture ( Fig. 1) .
Available therapies for varices and variceal hem orrhage can be classified according to whether they act on the physiological mechanisms of por tal hypertension.
Therapies that Reduce Portal Pressure
Splanchnic vasoconstrictors such as vasopressin and somatostatin (and their analogues, octreotide and vapreotide) are administered parenterally and are therefore restricted to use in an acute care setting. Nonselective betaadrenergic blockers af fect portal flow by means of both β 1 blockade (reduction of cardiac output) and β 2 blockade (splanchnic vasoconstriction). 17 Therefore, non selective betablockers such as propranolol or na dolol are better than selective betablockers be cause of broader mechanisms of action. They are administered orally and are used in the longterm treatment of portal hypertension.
Drugs that increase the delivery of nitric oxide to the intrahepatic circulation, such as nitrates and simvastatin, and drugs that block adrenergic ac tivity (e.g., prazosin and clonidine) or that block angiotensin (e.g., captopril, losartan, and irbesar tan) act by inducing intrahepatic vasodilatation. 17 Unfortunately, venodilators may also cause sys temic vasodilatation, with aggravation of sodium retention and renal vasoconstriction. 18, 19 An excep tion may be simvastatin, which acts on the dys functional intrahepatic endothelium without an effect on the systemic circulation. 20, 21 The combination of vasodilators and splanch nic vasoconstrictors, such as the combination of nonselective betablockers plus nitrates or carve dilol (a nonselective betablocker with an added vasodilatory effect through anti-α 1 adrenergic ac tivity), has an additive portal pressure-reducing effect but can also decrease arterial pressure. 22 Notably, none of the drugs mentioned above are approved in the United States for the treatment of portal hypertension. Their use in patients with portal hypertension is therefore considered off label.
A shunt connecting the hypertensive portal system and lowpressure systemic veins reverses portal hypertension; this can be achieved percu taneously through the placement of a transjugular intrahepatic portosystemic shunt or surgically.
Local Therapies without Portal PressureReducing Effects
Endoscopic procedures can be used to place elas tic bands on variceal columns (variceal ligation) or to inject sclerosing agents (variceal sclerother apy) or tissue adhesives (variceal obturation) into gastroesophageal varices. 23 These techniques can achieve variceal obliteration (sometimes called "eradication"). However, gastroesophageal varices will eventually recur; therefore, close endoscopic surveillance and retreatment are necessary. Other shorterterm temporizing local mea sures include balloon tamponade and placement of expandable esophageal stents. 24 
R isk Str atification for Patients w ith Porta l H y pertension
One of the main issues confounding screening of and therapeutic studies involving patients with cirrhosis is a lack of proper risk stratification. At a minimum, patients should be stratified accord ing to whether they have compensated or decom pensated cirrhosis. 25 In patients with compensated cirrhosis (i.e., those who do not have ascites, variceal hemor rhage, encephalopathy, or jaundice), risk stratifi cation starts with an assessment for the presence of gastroesophageal varices. Patients with gastro esophageal varices have a higher rate of death and a greater risk of decompensation than those with out gastroesophageal varices. 26 The recommended method to determine the presence and size of gastroesophageal varices is esophagogastrodu odenoscopy. 1,2,27 Less invasive methods such as capsule endoscopy are being investigated and may be preferred by patients; however, their accuracy in evaluating the presence of varices, red wale marks, and variceal size is still suboptimal. 27 Similarly, a ratio of platelet count (per cubic milli meter) to spleen size (the maximum bipolar di The initial mechanism in the development of portal hypertension in cirrhosis is an increase in vascular resistance to portal flow. A subsequent increase in portal venous inflow maintains the portal hypertensive state. Portal hypertension leads to the formation of portosystemic collaterals, of which the most clinically relevant are gastroesophageal varices. The increase in flow through these collaterals, enhanced by the presence of splanchnic vasodilatation and increased portal blood inflow, leads to variceal growth and rupture. This process is modulated by angiogenic factors. VEGF denotes vascular endothelial growth factor.
Copyright © 2010 Massachusetts Medical Society. All rights reserved.
Downloaded from www.nejm.org at CRAI UNIVERSITAT DE BARCELONA on March 9, 2010 .
ameter in millimeters by ultrasonography) above 909 has a high negative predictive value (i.e., the patient is unlikely to have varices). 28 However, this ratio requires further validation. 29 In patients without varices and in those with variceal hemorrhage, measurement of portal pres sure with the use of the hepatic venous pressure gradient (HVPG) is the best method to stratify risk. Portal hypertension is present when the HVPG is greater than 5 mm Hg, but it is consid ered clinically significant when the HVPG is greater than 10 mm Hg, because in patients with out varices, this pressure is the strongest predic tor of the development of varices, 5 clinical decom pensation, 30 and hepatocellular carcinoma. 31 In patients with variceal hemorrhage, an HVPG of more than 20 mm Hg (measured within 24 hours after admission) is the best predictor of a poor outcome. 32 In contrast, a reduction in the HVPG to less than 12 mm Hg or a reduction of more than 20% from the baseline value is associated with a decreased risk of variceal hemorrhage and im proved survival. 33, 34 The HVPG is obtained by means of catheter ization of a hepatic vein with a balloon catheter through a jugular or femoral vein. Although the procedure to obtain the HVPG is simple and safe (see the video, available with the full text of this article at NEJM.org), it is invasive and its use is not widespread in the United States. Standardization of the technique through the creation of multi society guidelines, certification, and quality con trol is needed to help bring the HVPG into wider clinical use. 3 Measurement of liver stiffness, a technique not yet widely available in the United States, is a non invasive method that correlates reasonably well with the HVPG, particularly at HVPG values below 10 mm Hg. 35 Therefore, it appears to be useful in identifying the presence of clinically significant portal hypertension. Notably, the presence of va rices (or collaterals on imaging studies) indicates that clinically significant portal hypertension is present.
The Child class or its laboratory components (the levels of bilirubin and albumin and the in ternational normalized ratio) correlate roughly with clinically significant portal hypertension 36 and can be used to stratify risk in both compen sated and decompensated cirrhosis. 26 In patients with variceal hemorrhage, Child class C has been associated with an HVPG of more than 20 mm Hg and a poor outcome. 11 The Model for EndStage Liver Disease score, which is used for organ alloca tion in liver transplantation, has been shown to predict the development of decompensation in patients without varices 30 and to predict 6week mortality after variceal hemorrhage. 37 Pr ev ention of Va r ices a nd a Fir s t Va r ice a l Hemor r h age Patients without gastroesophageal varices or with gastroesophageal varices that have never bled are at relatively low risk for bleeding and death, and therefore, therapies for these patients should be the least invasive. In patients without varices, treat ment with nonselective betablockers is not rec ommended because they do not prevent the devel opment of varices and are associated with side effects. 5 In patients with lowrisk, small varices (with out red wale marks and in the absence of severe liver disease), nonselective betablockers may de lay variceal growth and thereby prevent variceal hemorrhage. 38 These agents are considered op tional, given the limited existing evidence, the lowrisk setting, and the alternative of periodic screening for variceal growth.
In patients with small varices that are associ ated with a high risk of hemorrhage (varices with red wale marks or varices in a patient with Child class B or C disease), nonselective betablockers are recommended.
In patients with medium or large varices, ei ther nonselective betablockers or endoscopic var iceal ligation can be used, since a metaanalysis of highquality, randomized, controlled trials has shown equivalent efficacy and no differences in survival. 39 The advantages of nonselective beta blockers are that their cost is low, expertise is not required for their use, and they may prevent other complications, such as bleeding from portal hy pertensive gastropathy, ascites, and spontaneous bacterial peritonitis because they reduce portal pressure. 33, 40, 41 The disadvantages of these agents include relatively common contraindications and side effects (fatigue and shortness of breath) that preclude treatment or require discontinuation in 15 to 20% of patients. The advantages of endo scopic variceal ligation are that it can be performed at the time of screening endoscopy and that its side effects are less frequent. However, specific expertise is necessary, and there is potential for lethal hemorrhage from postprocedure ulcers. 17 Some centers perform endoscopic variceal liga tion in most patients, whereas other centers pre fer to use nonselective betablockers initially, switching to endoscopic variceal ligation in pa tients with intolerance or contraindications to nonselective betablockers; the latter is a rational approach. The schedule, doses, goals, and follow up of therapies for primary prophylaxis are shown in Table 2 (see Fig. 1 in the Supplementary Appen dix, available with the full text of this article at NEJM.org).
Carvedilol at low doses (6.25 to 12.5 mg per day) was compared with endoscopic variceal liga tion in a recent randomized, controlled trial. 42 Carvedilol was associated with lower rates of first variceal hemorrhage (10% vs. 23%) and had an acceptable sideeffect profile, unlike endoscopic variceal ligation, for which compliance was low and the rate of first hemorrhage was at the upper end of the range of rates in previous studies. 42 Whether carvedilol is more effective or better toler ated than nonselective betablockers remains to be determined.
Tr e atment of Acu te Va r ice a l Hemor r h age
The rate of death from acute variceal hemorrhage has been decreasing over the past two decades, probably as a result of improved general manage ment (with prophylactic antibiotics) and more ef fective therapies (endoscopic variceal ligation and vasoactive drugs). 43 Although therapy is not cur rently targeted at specific risk groups, recent data suggest that in patients at high risk (Child class C or an HVPG of >20 mm Hg), the approach should be more aggressive. Patients who have Child class A or B disease or who have an HVPG of less than 20 mm Hg have a low or intermediate risk and should receive stan dard therapy -specifically, the combination of a safe vasoconstrictor (terlipressin, somatostatin, or analogues such as octreotide or vapreotide, admin istered from the time of admission and maintained for 2 to 5 days) and endoscopic therapy (preferably endoscopic variceal ligation, performed at diag nostic endoscopy <12 hours after admission), 10,44 together with shortterm prophylactic antibiotics (either norfloxacin or ceftriaxone). 45, 46 The only vasoconstrictor currently available in the United States is octreotide. In other countries, the choice of vasoconstrictor depends on availability and cost. Antibiotic prophylaxis with ceftriaxone is rec ommended in patients with severe liver disease, particularly if they are receiving quinolone pro phylaxis, whereas others can receive oral norfloxa cin or intravenous ciprofloxacin (Table 3) .
Placement of a transjugular intrahepatic por tosystemic shunt is currently considered a salvage therapy for the 10 to 20% of patients in whom standard medical therapy fails (Fig. 2 in the Sup plementary Appendix). However, two randomized, controlled trials have shown that early placement of such a shunt (within 24 to 48 hours after ad mission) was associated with significant improve ment in survival among highrisk patients (i.e., patients with an HVPG >20 mm Hg 48 or with Child class C disease with a score between 10 and 13 points 49 [ Table 1 ]). Therefore, early place ment of a transjugular intrahepatic portosystemic shunt could be considered in these patients and, although this deserves further investigation, the decision to use this approach as salvage therapy in this highrisk population should be made sooner rather than later. In these patients, the use of recombinant factor VII has been found to be of little value. 12 Gastric varices are present in 20% of patients with cirrhosis, either in isolation or in combina tion with esophageal varices. Bleeding from fun dal varices is more severe and is associated with a higher rate of death than bleeding from gastro esophageal varices. 50 Endoscopic variceal obturation with the use of tissue adhesives such as Nbutyl2cyanoacrylate is more effective than endoscopic variceal liga tion in controlling initial hemorrhage and prevent ing rebleeding from gastric varices. 51,52 A trans jugular intrahepatic portosystemic shunt is also effective in patients with bleeding fundal varices. In a recent randomized, controlled trial in which endoscopic variceal obturation was used to con trol acute hemorrhage in all patients (with a 93% success rate), a transjugular intrahepatic porto systemic shunt was more effective than endoscop ic variceal obturation in preventing recurrent hem orrhage. 53 Even though fundal varices were the source of bleeding in less than half the patients included in these studies and vasoactive drugs have not been investigated, data suggest that endoscopic variceal obturation is the best endoscopic tech nique to control acute hemorrhage and the tran sjugular intrahepatic portosystemic shunt is more effective than variceal obturation in preventing recurrent hemorrhage. Among tissue adhesives, Nbutyl2cyanoacrylate is not available in the United States, and although the offlabel use of another adhesive, 2octyl cyanoacrylate, has been reported, 54 endoscopic variceal obturation requires careful attention to technique and is not free of serious complications. If an endoscopist with the requisite expertise is unavailable, placement of a transjugular intrahepatic portosystemic shunt should be considered firstline therapy when bleed ing is not controlled by vasoactive drugs.
Currently, treatment recommendations apply to all patients with variceal hemorrhage. Patients with Child class A disease have a good response to current therapies, with a minimal risk of death (0 to 5%). Whether pharmacologic therapy alone would suffice in these patients deserves further examination. Strategies are being investigated that may improve survival in patients with Child class C disease, but new strategies should be in vestigated for those at intermediate risk (Child class B).
Pr ev ention of R ecur r ent
Va r ice a l Hemor r h age Given the high recurrence rate, patients who sur vive an acute variceal hemorrhage should receive therapy to prevent recurrence before they are dis charged from the hospital. Combination pharma cologic therapy (nonselective betablockers plus nitrates) or combination endoscopic variceal liga tion plus drug therapy are warranted because of the high risk of recurrence, even though the side effects will be greater than those with single agent therapy (recommended for primary prophy laxis). These two strategies were compared in a ran domized, controlled trial that showed a signifi cantly lower rate of variceal rebleeding with a combination of endoscopic variceal ligation and drug therapy (nonselective betablockers plus ni trates) than with drug therapy alone. However, the rate of hemorrhage from all sources was not significantly different because of bleeding from esophageal ulcers induced by endoscopic variceal ligation. 55 A metaanalysis showed that rates of rebleeding (from all sources and from varices) are lower with a combination of endoscopic therapy plus drug therapy than with either therapy alone, but with out differences in survival. 56 Therefore, current guidelines recommend the combined use of en doscopic variceal ligation and nonselective beta blockers for the prevention of recurrent variceal hemorrhage, even in patients who have had a re current hemorrhage despite treatment with non selective betablockers or endoscopic variceal li gation for primary prophylaxis. In patients who are not candidates for endoscopic variceal ligation, the strategy would be to maximize portalpressure reduction by combining nonselective betablockers plus nitrates.
Patients who have rebleeding despite combined treatment with endoscopic variceal ligation and drugs at the recommended doses and schedule (Table 4) or surgical creation of a shunt; the two shunts are equally effective (Fig. 3 in the Supplementary Ap  pendix) . 57 The need for frequent revision of a transjugular intrahepatic portosystemic shunt, re ported in a randomized, controlled trial, 57 appears to have been overcome with the current use of coated stents, which have a significantly lower oc clusion rate. 58 The choice between a transjugular intrahepatic portosystemic shunt and surgery will therefore depend on local expertise and the pa tient's preference.
The rate of recurrent variceal hemorrhage is lowest (approximately 10%) among patients in whom the HVPG decreases to less than 12 mm Hg or is reduced by more than 20% from the baseline value. 9,34 Perhaps the most rational approach to the prevention of recurrent hemorrhage would be to choose therapies on the basis of the HVPG response; however, the issue will remain unre solved until randomized, controlled trials show that HVPGguided therapy is superior to the cur rent empirical treatment.
Other than the HVPG response, therapeutic ap proaches in patients who have recovered from var iceal hemorrhage are not targeted at specific risk groups. Given that the severity of liver disease has been consistently shown to be a good predictor of recurrent hemorrhage and death, the Child clas sification could also be a good way to stratify pa tients according to risk. Although patients with Child class A disease may require only pharma cologic therapy, more aggressive combination therapies would be required in patients with a high risk (i.e., patients with Child class B or C disease and patients on the transplantation list).
Speci a l Sit uations for w hich Ther e Is Limited or No Ev idence

Portal Hypertensive Gastropathy
Portal hypertensive gastropathy is a portal hyper tension-related gastrointestinal mucosal lesion characterized by ectatic gastric mucosal vessels mostly in the fundus and body of the stomach. The presence of gastroesophageal varices and the Child class are predictive of portal hypertensive gastropathy, whereas its development or its pro gression from mild to severe correlates only with the Child class. 59 Although the prevalence of por tal hypertensive gastropathy is higher among pa tients who have undergone endoscopic therapy (sclerotherapy or endoscopic variceal ligation) than 
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al. The use of selfexpanding metal stents to treat acute esophageal variceal bleeding.
